Cyclopharm Statistics

Total Valuation

Cyclopharm has a market cap or net worth of AUD 125.58 million. The enterprise value is 113.30 million.

Market Cap	125.58M
Enterprise Value	113.30M

Important Dates

The next estimated earnings date is Monday, May 26, 2025.

Earnings Date	May 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Cyclopharm has 111.14 million shares outstanding. The number of shares has increased by 11.05% in one year.

Current Share Class	n/a
Shares Outstanding	111.14M
Shares Change (YoY)	+11.05%
Shares Change (QoQ)	+14.69%
Owned by Insiders (%)	11.28%
Owned by Institutions (%)	22.71%
Float	56.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	188.94
PS Ratio	4.55
PB Ratio	2.94
P/TBV Ratio	3.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.59
EV / Sales	4.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.47

Financial Position

The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.19.

Current Ratio	3.99
Quick Ratio	2.54
Debt / Equity	0.19
Debt / EBITDA	n/a
Debt / FCF	-0.62
Interest Coverage	-51.35

Financial Efficiency

Return on equity (ROE) is -35.20% and return on invested capital (ROIC) is -20.75%.

Return on Equity (ROE)	-35.20%
Return on Assets (ROA)	-16.80%
Return on Invested Capital (ROIC)	-20.75%
Return on Capital Employed (ROCE)	-28.19%
Revenue Per Employee	290,238
Profits Per Employee	-138,922
Employee Count	95
Asset Turnover	0.51
Inventory Turnover	0.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.43% in the last 52 weeks. The beta is 0.86, so Cyclopharm's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-35.43%
50-Day Moving Average	1.35
200-Day Moving Average	1.56
Relative Strength Index (RSI)	42.59
Average Volume (20 Days)	128,283

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cyclopharm had revenue of AUD 27.57 million and -13.20 million in losses. Loss per share was -0.13.

Revenue	27.57M
Gross Profit	17.93M
Operating Income	-14.52M
Pretax Income	-13.07M
Net Income	-13.20M
EBITDA	-13.69M
EBIT	-14.52M
Loss Per Share	-0.13

Full Income Statement

Balance Sheet

The company has 20.57 million in cash and 8.29 million in debt, giving a net cash position of 12.28 million or 0.11 per share.

Cash & Cash Equivalents	20.57M
Total Debt	8.29M
Net Cash	12.28M
Net Cash Per Share	0.11
Equity (Book Value)	42.73M
Book Value Per Share	0.38
Working Capital	31.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.57 million and capital expenditures -803,534, giving a free cash flow of -13.38 million.

Operating Cash Flow	-12.57M
Capital Expenditures	-803,534
Free Cash Flow	-13.38M
FCF Per Share	-0.12

Full Cash Flow Statement

Margins

Gross margin is 65.04%, with operating and profit margins of -52.68% and -47.87%.

Gross Margin	65.04%
Operating Margin	-52.68%
Pretax Margin	-47.41%
Profit Margin	-47.87%
EBITDA Margin	-49.65%
EBIT Margin	-52.68%
FCF Margin	n/a

Dividends & Yields

Cyclopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.05%
Shareholder Yield	-11.05%
Earnings Yield	-10.51%
FCF Yield	-10.65%

Dividend Details

Stock Splits

The last stock split was on May 28, 2012. It was a reverse split with a ratio of 0.2.

Last Split Date	May 28, 2012
Split Type	Reverse
Split Ratio	0.2

Scores

Cyclopharm has an Altman Z-Score of 4.42.

Altman Z-Score	4.42
Piotroski F-Score	n/a